The
rational design of cancer theranostics with natural diagnostic
information and therapeutic behavior has been considered to be a big
challenge, since common theranostics from photothermal and photodynamic
therapy need to be activated with external stimuli of photoirradiation
to enable the chemotherapeutic effects. In this contribution, we have
designed and synthesized a series of simple theranostic agents, TPA-N-n
(n = 4, 8, 12),
which could accumulate at the tumor site over 48 h and indicate superior
antiproliferative performance in vivo. TPA-N-n
was constructed with electron donor triphenylamine-acceptor
benzothiadiazole-mitochondria-targeting moiety pyridinium. Complex TPA-N-8 indicated the best cytotoxicity to cancerous HeLa
cells, with an IC50 value of 4.3 μM, and could self-assemble
to a nanosphere with a size of 161.2 nm in the DMSO/PBS solution.
It is worth noting that TPA-N-8 could accumulate in the
mitochondria and produce major ROS species O2•– and OH• as well as small amounts of 1O2 without photoirradiation. Oxidative DNA damage is initiated
due to the imbalance of intracellular redox homeostasis from the significant
ROS storm. Multimodal synergistic therapy for HeLa cells was activated,
as the PINK1-mediated mitophagy from the damaged mitochondria and
DNA damage responsive (DDR) induced necroptosis and autophagy. This
work not only provided a successful D–A type theranostic agent
with superior anticancer performance from multimodal synergistic therapy
but also further demonstrated the high efficacy of a mitochondria-targeting
strategy for cancer treatment.